![FDA begins process that will end the use of bevacizumab (Avastin®) for metastatic breast cancer.](/sites/default/files/assets/news/images/ln-angiogenesis.jpg)
The Food and Drug Administration (FDA) has begun the process of withdrawing the approval of bevacizumab (Avastin®) for the treatment of breast cancer. The agency states that the benefits of Avastin® do not outweigh the risks for this cancer type.
Learn More